PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.

Kambiz RahbarM BoegemannA YordanovaM EveslageM SchäfersM EsslerH Ahmadzadehfar

Published in: European journal of nuclear medicine and molecular imaging (2017)

177Lu-PSMA-617 RLT is a new effective therapeutic and seems to prolong survival in patients with advanced mCRPC pretreated with chemotherapy, abiraterone and/or enzalutamide.

Keyphrases

prostate cancer
pet ct
pet imaging
locally advanced
squamous cell carcinoma
free survival
small cell lung cancer
computed tomography
radiation therapy
drug delivery
positron emission tomography